GeneScience Pharmaceuticals Co., Ltd. Sustainability Profile
GeneScience Pharmaceuticals Co., Ltd., commonly referred to as GeneScience, is a leading biopharmaceutical company headquartered in China (CN). Established in 2002, the company has made significant strides in the biotechnology sector, focusing on the research, development, and production of innovative biopharmaceuticals. With a strong presence in both domestic and international markets, GeneScience excels in areas such as recombinant proteins, monoclonal antibodies, and biosimilars. Their flagship products, including the well-regarded EPO and G-CSF, are distinguished by their high quality and efficacy, setting them apart in a competitive landscape. Recognised for its commitment to advancing healthcare, GeneScience has achieved notable milestones, including numerous regulatory approvals and partnerships that enhance its market position. As a pioneer in the biopharmaceutical industry, GeneScience continues to drive innovation and improve patient outcomes globally.
DitchCarbon Score
How does GeneScience Pharmaceuticals Co., Ltd.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
GeneScience Pharmaceuticals Co., Ltd.'s score of 22 is lower than 79% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
GeneScience Pharmaceuticals Co., Ltd.'s reported carbon emissions
GeneScience Pharmaceuticals Co., Ltd., headquartered in China (CN), currently does not report specific carbon emissions data, as indicated by the absence of emissions figures. The company is a current subsidiary of Changchun High-Tech Industry (Group) Co., Ltd., which may influence its climate commitments and reporting practices. As of now, GeneScience Pharmaceuticals has not established any documented reduction targets or commitments under the Science Based Targets initiative (SBTi) or other climate initiatives. This lack of specific targets suggests that the company may still be in the early stages of developing a comprehensive climate strategy. Given the absence of direct emissions data and reduction initiatives, it is essential for GeneScience Pharmaceuticals to consider setting measurable climate goals and participating in recognised frameworks to enhance its sustainability profile and align with industry standards.
How Carbon Intensive is GeneScience Pharmaceuticals Co., Ltd.'s Industry?
How Carbon Intensive is GeneScience Pharmaceuticals Co., Ltd.'s Location?
GeneScience Pharmaceuticals Co., Ltd.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
GeneScience Pharmaceuticals Co., Ltd. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
